综述 |
|
|
|
|
外泌体靶向递药在肿瘤治疗中的进展 |
吕慧中,赵晨辰,朱链(),许娜() |
武汉科技大学生命科学与健康学院 生物医学研究院 武汉 430065 |
|
Progress of Using Exosome for Drug Targeted Delivery in Tumor Therapy |
LV Hui-zhong,ZHAO Chen-chen,ZHU Lian(),XU Na() |
Biomedical Research Institute, College of Life Sciences and Health, Wuhan University of Science and Technology, Wuhan 430065,China |
引用本文:
吕慧中,赵晨辰,朱链,许娜. 外泌体靶向递药在肿瘤治疗中的进展[J]. 中国生物工程杂志, 2021, 41(5): 79-86.
LV Hui-zhong,ZHAO Chen-chen,ZHU Lian,XU Na. Progress of Using Exosome for Drug Targeted Delivery in Tumor Therapy. China Biotechnology, 2021, 41(5): 79-86.
链接本文:
https://manu60.magtech.com.cn/biotech/CN/10.13523/j.cb.2012045
或
https://manu60.magtech.com.cn/biotech/CN/Y2021/V41/I5/79
|
[1] |
Thun M J, DeLancey J O, Center M M, et al. The global burden of cancer: priorities for prevention. Carcinogenesis, 2010,31(1):100-110.
doi: 10.1093/carcin/bgp263
|
[2] |
Shi H H, Xu M, Zhu J H, et al. Programmed co-delivery of platinum nanodrugs and gemcitabine by a clustered nanocarrier for precision chemotherapy for NSCLC tumors. Journal of Materials Chemistry B, 2020,8(2):332-342.
doi: 10.1039/C9TB02055A
|
[3] |
Théry C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nature Reviews Immunology, 2002,2(8):569-579.
doi: 10.1038/nri855
|
[4] |
Huotari J, Helenius A. Endosome maturation. The EMBO Journal, 2011,30(17):3481-3500.
doi: 10.1038/emboj.2011.286
pmid: 21878991
|
[5] |
Hessvik N P, Llorente A. Current knowledge on exosome biogenesis and release. Cellular and Molecular Life Sciences, 2018,75(2):193-208.
doi: 10.1007/s00018-017-2595-9
|
[6] |
Kowal J, Tkach M, de Théry C. Biogenesis and secretion of exosomes. Current Opinion in Cell Biology, 2014,29:116-125.
doi: 10.1016/j.ceb.2014.05.004
|
[7] |
Escola J M, Kleijmeer M J, Stoorvogel W, et al. Selective enrichment of tetraspan proteins on the internal vesicles of multivesicular endosomes and on exosomes secreted by human B-lymphocytes. Journal of Biological Chemistry, 1998,273(32):20121-20127.
doi: 10.1074/jbc.273.32.20121
|
[8] |
Eken C, Gasser O, Zenhaeusern G, et al. Polymorphonuclear neutrophil-derived ectosomes interfere with the maturation of monocyte-derived dendritic cells. Journal of Immunology, 2008,180(2):817-824.
doi: 10.4049/jimmunol.180.2.817
|
[9] |
Batrakova E V, Kim M S. Using exosomes, naturally-equipped nanocarriers, for drug delivery. Journal of Controlled Release, 2015,219:396-405.
doi: S0168-3659(15)30042-0
pmid: 26241750
|
[10] |
Chen H L, Li J J, Jiang F, et al. MicroRNA-4461 derived from bone marrow mesenchymal stem cell exosomes inhibits tumorigenesis by downregulating COPB2 expression in colorectal cancer. Bioscience, Biotechnology, and Biochemistry, 2020,84(2):338-346.
doi: 10.1080/09168451.2019.1677452
|
[11] |
Katakowski M, Buller B, Zheng X G, et al. Exosomes from marrow stromal cells expressing miR-146b inhibit glioma growth. Cancer Letters, 2013,335(1):201-204.
doi: 10.1016/j.canlet.2013.02.019
pmid: 23419525
|
[12] |
Ono M, Kosaka N, Tominaga N, et al. Exosomes from bone marrow mesenchymal stem cells contain a microRNA that promotes dormancy in metastatic breast cancer cells. Science Signaling, 2014, 7(332): ra63.
doi: 10.1126/scisignal.2005231
|
[13] |
Xie C, Du L Y, Guo F Y, et al. Exosomes derived from microRNA-101-3p-overexpressing human bone marrow mesenchymal stem cells suppress oral cancer cell proliferation, invasion, and migration. Molecular and Cellular Biochemistry, 2019,458(1-2):11-26.
doi: 10.1007/s11010-019-03526-7
|
[14] |
Sanderson R D, Bandari S K, Vlodavsky I. Proteases and glycosidases on the surface of exosomes: Newly discovered mechanisms for extracellular remodeling. Matrix Biology, 2019, 75-76:160-169.
|
[15] |
Ludwig N, Gillespie D G, Reichert T E, et al. Purine metabolites in tumor-derived exosomes may facilitate immune escape of head and neck squamous cell carcinoma. Cancers, 2020,12(6):1602.
doi: 10.3390/cancers12061602
|
[16] |
Haderk F, Schulz R, Iskar M, et al. Tumor-derived exosomes modulate PD-L1 expression in monocytes. Science Immunology, 2017, 2(13): eaah5509.
|
[17] |
Johnsen K B, Gudbergsson J M, Skov M N, et al. A comprehensive overview of exosomes as drug delivery vehicles:Endogenous nanocarriers for targeted cancer therapy. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2014,1846(1):75-87.
doi: 10.1016/j.bbcan.2014.04.005
|
[18] |
Gallatin W M, Weissman I L, Butcher E C. A cell-surface molecule involved in organ-specific homing of lymphocytes. Nature, 1983,304(5921):30-34.
pmid: 6866086
|
[19] |
Liesveld J L, Sharma N, Aljitawi O S. Stem cell homing: From physiology to therapeutics. Stem Cells (Dayton, Ohio), 2020,38(10):1241-1253.
|
[20] |
李艾, 张添源, 高建青. 间充质干细胞的肿瘤归巢特性及其肿瘤靶向治疗应用研究进展. 浙江大学学报(医学版), 2020,49(1):20-34.
|
|
Li A, Zhang T Y, Gao J Q. Progress on utilizing mesenchymal stem cells as cellular delivery system for targeting delivery of as drug/gene for anti-tumor therapy. Journal of Zhejiang University (Medical Sciences), 2020,49(1):20-34.
|
[21] |
Harrell C R, Jovicic N, Djonov V, et al. Therapeutic use of mesenchymal stem cell-derived exosomes: from basic science to clinics. Pharmaceutics, 2020,12(5):474.
doi: 10.3390/pharmaceutics12050474
|
[22] |
Myint P K, Park E J, Gaowa A, et al. Targeted remodeling of breast cancer and immune cell homing niches by exosomal integrins. Diagnostic Pathology, 2020,15(1):38.
doi: 10.1186/s13000-020-00959-3
|
[23] |
Zhou Y, Zhou W X, Chen X L, et al. Bone marrow mesenchymal stem cells-derived exosomes for penetrating and targeted chemotherapy of pancreatic cancer. Acta Pharmaceutica Sinica B, 2020,10(8):1563-1575.
doi: 10.1016/j.apsb.2019.11.013
pmid: 32963950
|
[24] |
Wei H X, Chen J Y, Wang S L, et al. A nanodrug consisting of doxorubicin and exosome derived from mesenchymal stem cells for osteosarcoma treatment in vitro. International Journal of Nanomedicine, 2019,14:8603-8610.
doi: 10.2147/IJN
|
[25] |
Qiao L, Hu S Q, Huang K, et al. Tumor cell-derived exosomes home to their cells of origin and can be used as Trojan horses to deliver cancer drugs. Theranostics, 2020,10(8):3474-3487.
doi: 10.7150/thno.39434
pmid: 32206102
|
[26] |
Yong T Y, Zhang X Q, Bie N N, et al. Tumor exosome-based nanoparticles are efficient drug carriers for chemotherapy. Nature Communications, 2019,10:3838.
doi: 10.1038/s41467-019-11718-4
|
[27] |
Zhao L W, Gu C Y, Gan Y, et al. Exosome-mediated siRNA delivery to suppress postoperative breast cancer metastasis. Journal of Controlled Release, 2020,318:1-15.
doi: 10.1016/j.jconrel.2019.12.005
|
[28] |
Smyth T, Kullberg M, Malik N, et al. Biodistribution and delivery efficiency of unmodified tumor-derived exosomes. Journal of Controlled Release, 2015,199:145-155.
doi: 10.1016/j.jconrel.2014.12.013
|
[29] |
Zhu W, Huang L, Li Y H, et al. Exosomes derived from human bone marrow mesenchymal stem cells promote tumor growth in vivo. Cancer Letters, 2012,315(1):28-37.
doi: 10.1016/j.canlet.2011.10.002
|
[30] |
Chapel A, Bertho J M, Bensidhoum M, et al. Mesenchymal stem cells home to injured tissues when co-infused with hematopoietic cells to treat a radiation-induced multi-organ failure syndrome. The Journal of Gene Medicine, 2003,5(12):1028-1038.
doi: 10.1002/(ISSN)1521-2254
|
[31] |
Munagala R, Aqil F, Jeyabalan J, et al. Bovine milk-derived exosomes for drug delivery. Cancer Letters, 2016,371(1):48-61.
doi: 10.1016/j.canlet.2015.10.020
pmid: 26604130
|
[32] |
Li Z F, Wang H Z, Yin H R, et al. Arrowtail RNA for ligand display on ginger exosome-like nanovesicles to systemic deliver siRNA for cancer suppression. Scientific Reports, 2018,8:14644.
doi: 10.1038/s41598-018-32953-7
|
[33] |
Zheng Z, Li Z F, Xu C C, et al. Folate-displaying exosome mediated cytosolic delivery of siRNA avoiding endosome trapping. Journal of Controlled Release, 2019, 311-312:43-49.
doi: S0168-3659(19)30505-X
pmid: 31446085
|
[34] |
Yu M Y, Gai C C, Li Z, et al. Targeted exosome-encapsulated erastin induced ferroptosis in triple negative breast cancer cells. Cancer Science, 2019,110(10):3173-3182.
doi: 10.1111/cas.v110.10
|
[35] |
Wang J, Dong Y, Li Y W, et al. Designer exosomes for active targeted chemo-photothermal synergistic tumor therapy. Advanced Functional Materials, 2018,28(18):1707360.
doi: 10.1002/adfm.v28.18
|
[36] |
Large D E, Soucy J R, Hebert J, et al. Advances in receptor-mediated, tumor-targeted drug delivery. Advanced Therapeutics, 2019,2(1):1800091.
doi: 10.1002/adtp.v2.1
|
|
Large D E, Soucy J R, Hebert J, et al. Advances in receptor-mediated, tumor-targeted drug delivery. Advanced Therapeutics, 2019,2(1):1800091.
|
[37] |
Nie W D, Wu G H, Zhang J F, et al. Responsive exosome nano-bioconjugates for synergistic cancer therapy. Angewandte Chemie (International Ed in English), 2020,59(5):2018-2022.
doi: 10.1002/anie.v59.5
|
[38] |
Cheng Q Q, Shi X J, Han M L, et al. Reprogramming exosomes as nanoscale controllers of cellular immunity. Journal of the American Chemical Society, 2018,140(48):16413-16417.
doi: 10.1021/jacs.8b10047
|
[39] |
Shi X J, Cheng Q Q, Hou T L, et al. Genetically engineered cell-derived nanoparticles for targeted breast cancer immunotherapy. Molecular Therapy, 2020,28(2):536-547.
doi: 10.1016/j.ymthe.2019.11.020
|
[40] |
Si Y N, Kim S, Zhang E, et al. Targeted exosomes for drug delivery: biomanufacturing, surface tagging, and validation. Biotechnology Journal, 2020,15(1):e1900163.
|
[41] |
Li Y, Gao Y, Gong C N, et al. A33 antibody-functionalized exosomes for targeted delivery of doxorubicin against colorectal cancer. Nanomedicine: Nanotechnology, Biology and Medicine, 2018,14(7):1973-1985.
doi: 10.1016/j.nano.2018.05.020
|
[42] |
Samaranayake H, Wirth T, Schenkwein D, et al. Challenges in monoclonal antibody-based therapies. Annals of Medicine, 2009,41(5):322-331.
doi: 10.1080/07853890802698842
pmid: 19234897
|
[43] |
Hung M E, Leonard J N. Stabilization of exosome-targeting peptides via engineered glycosylation. Journal of Biological Chemistry, 2015,290(13):8166-8172.
doi: 10.1074/jbc.M114.621383
|
[44] |
Gomari H, Moghadam M F, Soleimani M, et al. Targeted delivery of doxorubicin to HER2 positive tumor models. International Journal of Nanomedicine, 2019,14:5679-5690.
doi: 10.2147/IJN.S210731
pmid: 31413568
|
[45] |
Limoni S K, Moghadam M F, Moazzeni S M, et al. Engineered exosomes for targeted transfer of siRNA to HER2 positive breast cancer cells. Applied Biochemistry and Biotechnology, 2019,187(1):352-364.
doi: 10.1007/s12010-018-2813-4
|
[46] |
Gomari H, Moghadam M F, Soleimani M. Targeted cancer therapy using engineered exosome as a natural drug delivery vehicle. OncoTargets and Therapy, 2018,11:5753-5762.
doi: 10.2147/OTT.S173110
pmid: 30254468
|
[47] |
Cao Y, Wu T T, Zhang K, et al. Engineered exosome-mediated near-infrared-II region V2C quantum dot delivery for nucleus-target low-temperature photothermal therapy. ACS Nano, 2019,13(2):1499-1510.
doi: 10.1021/acsnano.8b07224
pmid: 30677286
|
[48] |
Gong C N, Tian J, Wang Z, et al. Functional exosome-mediated co-delivery of doxorubicin and hydrophobically modified microRNA 159 for triple-negative breast cancer therapy. Journal of Nanobiotechnology, 2019,17(1):93.
doi: 10.1186/s12951-019-0526-7
|
[49] |
赵莉娟, 郑江红, 柳向东, 等. iRGD-外泌体-阿霉素抑制恶性黑色素瘤体外增殖的研究. 组织工程与重建外科杂志, 2017,13(1):25-28.
|
|
Zhao L J, Zheng J H, Liu X D, et al. The inhibition of iRGD-exosomes-doxorubicin on the proliferation of malignant melanoma in vitro. Journal of Tissue Engineering and Reconstructive Surgery, 2017,13(1):25-28.
|
[50] |
Cheng H, Fan J H, Zhao L P, et al. Chimeric peptide engineered exosomes for dual-stage light guided plasma membrane and nucleus targeted photodynamic therapy. Biomaterials, 2019,211:14-24.
doi: S0142-9612(19)30268-6
pmid: 31078049
|
[51] |
Bellavia D, Raimondo S, Calabrese G, et al. Interleukin 3- receptor targeted exosomes inhibit in vitro and in vivo Chronic Myelogenous Leukemia cell growth. Theranostics, 2017,7(5):1333-1345.
doi: 10.7150/thno.17092
pmid: 28435469
|
[52] |
Liang G F, Kan S, Zhu Y L, et al. Engineered exosome-mediated delivery of functionally active miR-26a and its enhanced suppression effect in HepG2 cells. International Journal of Nanomedicine, 2018,13:585-599.
doi: 10.2147/IJN
|
[53] |
Jia G, Han Y, An Y L, et al. NRP-1 targeted and cargo-loaded exosomes facilitate simultaneous imaging and therapy of glioma in vitro and in vivo. Biomaterials, 2018,178:302-316.
doi: 10.1016/j.biomaterials.2018.06.029
|
[54] |
Xin L, Yuan Y W, Liu C, et al. Preparation of internalizing RGD-modified recombinant methioninase exosome active targeting vector and antitumor effect evaluation. Digestive Diseases and Sciences, 2021,66(4):1045-1053.
doi: 10.1007/s10620-020-06262-x
|
[55] |
Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proceedings of the National Academy of Sciences of the United States of America, 1989,86(24):10024-10028.
|
[56] |
Porter D L, Levine B L, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. The New England Journal of Medicine, 2011,365(8):725-733.
doi: 10.1056/NEJMoa1103849
pmid: 21830940
|
[57] |
Jackson H J, Rafiq S, Brentjens R J. Driving CAR T-cells forward. Nature Reviews Clinical Oncology, 2016,13(6):370-383.
doi: 10.1038/nrclinonc.2016.36
|
[58] |
Mahadeo K M, Khazal S J, Abdel-Azim H, et al. Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. Nature Reviews Clinical Oncology, 2019,16(1):45-63.
doi: 10.1038/s41571-018-0075-2
|
[59] |
Newick K, O’Brien S, Moon E, et al. CAR T cell therapy for solid tumors. Annual Review of Medicine, 2017,68(1):139-152.
doi: 10.1146/annurev-med-062315-120245
|
[60] |
Brudno J N, Kochenderfer J N. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood, 2016,127(26):3321-3330.
doi: 10.1182/blood-2016-04-703751
|
[61] |
Maude S L, Barrett D, Teachey D T, et al. Managing cytokine release syndrome associated with novel T cell-engaging therapies. The Cancer Journal, 2014,20(2):119-122.
doi: 10.1097/PPO.0000000000000035
|
[62] |
Tang X J, Sun X Y, Huang K M, et al. Therapeutic potential of CAR-T cell-derived exosomes: a cell-free modality for targeted cancer therapy. Oncotarget, 2015,6(42):44179-44190.
doi: 10.18632/oncotarget.v6i42
|
[63] |
Fu W Y, Lei C H, Liu S W, et al. CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity. Nature Communications, 2019,10:4355.
doi: 10.1038/s41467-019-12321-3
|
[64] |
Rafiq S, Hackett C S, Brentjens R J. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nature Reviews Clinical Oncology, 2020,17(3):147-167.
doi: 10.1038/s41571-019-0297-y
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|